Acute Allograft Rejection following Interferon Therapy for Hepatitis C in Recipients who have Returned to Dialysis after Kidney Transplant Failure: Case Study

2014 ◽  
Vol 37 (11) ◽  
pp. 803-808 ◽  
Author(s):  
Fabrizio Fabrizi ◽  
Roberta D'Ambrosio ◽  
Francesco Pallotti ◽  
Luisa Berardinelli ◽  
Piergiorgio Messa ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Kidney Transplant ◽  
Allograft Rejection ◽  
Interferon Therapy ◽  
Acute Allograft Rejection ◽  
Transplant Failure

Prolonged Psychosis Associated With Interferon Therapy in a Patient With Hepatitis C: Case Study and Literature Review

2009 ◽  
Vol 50 (5) ◽  
pp. 538-542 ◽  
Author(s):  
Yi-Chun Cheng ◽  
Chun-Chih Chen ◽  
Ai-Sheng Ho ◽  
Nan-Ying Chiu
Keyword(s):  
Hepatitis C ◽  
Literature Review ◽  
Interferon Therapy

scholarly journals Comparison of clinical outcome of induction immunosuppressive therapy with thymoglobulin and standard therapy in kidney transplantation; a randomized double-blind clinical trial

2019 ◽  
Vol 9 (1) ◽  
pp. e08-e08
Author(s):  
Heshmatollah Shahbazian ◽  
Ali Ghorbani ◽  
Fatemeh Hayati ◽  
Seyed Seifollah Beladi Mousavi ◽  
Leila Sabetnia ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Kidney Transplantation ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Allograft Rejection ◽  
Control Group ◽  
Case Group ◽  
Transplant Recipients ◽  
Acute Allograft Rejection ◽  
Kidney Transplant Recipients

Introduction: Thymoglobulin is a lymphocyte-depleting polyclonal antibody, administered for induction therapy at the time of kidney transplantation to reduce the risk of acute allograft rejection. The appropriate dosage and duration of therapy is controversial. The higher dosages are associated with infection and malignancy. Objectives: In this study efficacy and safety of lower dosage (in comparison with previous studies) of thymoglobulin in kidney transplant recipients was evaluated. Patients and Methods: In this clinical trial, 106 adult kidney transplant recipients, were randomized before transplantation in two groups (case and control). The case group (53 patients) were received induction therapy with thymoglobulin (1.5 mg/kg/d for 3 days) and the control group (53 patients) were received non-induction regiment. Delayed graft function (DGF), glomerular filtration rate (GFR), acute allograft rejection and thymoglobulin complications were evaluated during the first post-transplantation year. Results: Around 106 kidney transplant recipients were enrolled (71 or 66.98% deceased donor) to the study. No significant statistical differences were found in GFR at the time of discharge from hospital (P=0.399) and at 1 year (P=0.851) and acute allograft rejection (P= 0.304) between two groups. Graft survival (73.5% in case group versus 81.1% in control group, P=0.392) at month 12th was similar among groups. Additionally, no significant differences of acute allograft rejection in recipient from deceased or living donor between two groups were detected. There was a higher incidence of DGF in the control group (26.4%) than the thymoglobulin group (5.8%) and the difference was statistically significant (P= 0.004). Thrombocytopenia (17% versus 49.1%, P<0.001) and leukopenia (11.3% versus 50.9%, P<0.001) were also significantly higher in the case group. Conclusion: While the incidence of DGF was reduced in thymoglobulin group, the short-term acute allograft rejection rate was not reduced compared to the control group. However, our results require further consideration with larger samples

A 20-YEAR CASE STUDY OF A KIDNEY TRANSPLANT RECIPIENT WITH CHRONIC ACTIVE HEPATITIS C

1998 ◽  
Vol 65 (1) ◽  
pp. 134-138 ◽  
Author(s):  
Yasuji Ichikawa ◽  
Masahiro Kyo ◽  
Touru Hanafusa ◽  
Takashi Kohro ◽  
Hidefumi Kishikawa ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Transplant Recipient ◽  
Kidney Transplant ◽  
Chronic Active Hepatitis ◽  
Kidney Transplant Recipient

De Novo Membrano-Proliferative Nephritis Following Interferon Therapy for Chronic Hepatitis C (Case Study and Literature Review)

2013 ◽  
Vol 59 (3) ◽  
pp. 691-695 ◽  
Author(s):  
Fabrizio Fabrizi ◽  
Alessio Aghemo ◽  
Gabriella Moroni ◽  
Patrizia Passerini ◽  
Roberta D’Ambrosio ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Literature Review ◽  
Chronic Hepatitis C ◽  
Interferon Therapy ◽  
De Novo

scholarly journals BK Virus and Cytomegalovirus Coinfections in Kidney Transplantation and Their Impact on Allograft Loss

2021 ◽  
Vol 10 (17) ◽  
pp. 3779
Author(s):  
Sabina Herrera ◽  
Javier Bernal-Maurandi ◽  
Frederic Cofan ◽  
Pedro Ventura ◽  
Maria Angeles Marcos ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Allograft Rejection ◽  
Cytomegalovirus Infection ◽  
Graft Loss ◽  
Graft Function ◽  
Bk Virus ◽  
Kidney Graft ◽  
Acute Allograft Rejection ◽  
Kidney Transplant Recipients ◽  
Cmv Infection

We aimed to ascertain the interaction and effects of combined reactivations of BK virus and cytomegalovirus on kidney graft function. All consecutive kidney transplant recipients (KTR) between 2003 and 2016 were included. Of 1976 patients who received a kidney transplant, 23 (1.2%) presented BKV-associated nephropathy (BKVAN). Factors independently associated with BKVAN were diabetes mellitus (odds ratios (OR) 3.895%, confidence intervals (CI) (1.4–10.5)), acute allograft rejection (OR 2.8 95%, CI (1.1–7.6)) and nephrostomy requirement (OR 4.195%, CI (1.3–13)). Cytomegalovirus infection was diagnosed in 19% of KTR patients. Recipients with BKVAN presented more frequently with cytomegalovirus (CMV) infection compared to patients without BKVAN (39% vs. 19%, p = 0.02). Acute allograft rejection (OR 2.95%, CI (1.4–2.4)) and nephrostomy requirement (OR 2.95%, CI (1.2–3)) were independently associated with CMV infection. Sixteen patients (69%) with BKVAN had graft dysfunction at one-year post-transplant and eight of them (35%) lost their graft. Patients presenting with BKVAN and graft loss presented more frequently a cytomegalovirus infection (OR 2.295%, CI (1.3–4.3)). In conclusion, we found a relation between CMV infection and graft loss in patients presenting BKVAN, suggesting that patients with CMV reactivation should be actively screened for BKV.

Sign in / Sign up

Export Citation Format

Share Document